Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DSM To Lower Its Stake In Huabei Pharmaceutical Group

This article was originally published in PharmAsia News

Executive Summary

DSM and Huabei Pharmaceutical Group recently made substantial progress in its strategic collaboration (PharmAsia News, Jan. 12, 2009). However, an informed source discloses that DSM's stake in the Huabei company will be lower than the previously determined 25 percent as a higher share proportion will not likely get approval from the State-owned Assets Supervision and Administration Commission of Hebei Province. The parties have revised the agreement and submitted the application to the relevant authorities. The collaboration will be announced after the lunar new year, starting with raw drug materials business, namely antibiotics and vitamins. At the same time, Huabei Pharmaceutical Group is seeking its second strategic investor and candidates include state-owned ChemChina. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel